Phase 3 trial

July 16, 2019July 16, 2019

Enrollment Completed for Phase 3 REFALS Trial Evaluating Levosimendan in ALS Patients

News

The Phase 3 REFALS trial exploring the impact of oral levosimendan (ODM-109) in patients with amyotrophic lateral sclerosis (ALS) has completed its target enrollment, the therapy’s manufacturer, Orion, announced. ... Read more

September 27, 2018

FDA Gives OK to Medicinova’s Phase 3 Clinical Trial Plan for Ibudilast in ALS

News

The U.S. Food and Drug Administration has given positive feedback to MediciNova’s Phase 3 developmental plan for its investigational therapy ibudilast (MN-166) for amyotrophic lateral sclerosis (ALS). Following the ... Read more

July 26, 2018July 26, 2018

BrainStorm Update Ensures Funds for Completion of Phase 3 NurOwn Trial, Announces 2 New Patents

News

BrainStorm Cell Therapeutics’ latest financial results guarantee enough capital to complete the ongoing Phase 3 trial of amyotrophic lateral sclerosis (ALS) therapy candidate NurOwn, according to an update from ... Read more

July 10, 2018July 10, 2018

Phase 3 Trial of Oral Levosimendan as Respiratory Treatment for ALS Recruiting in US, Europe and Australia

News

A new Phase 3 trial evaluating levosimendan (also known as ODM-109), an oral treatment by Orion for breathing problems in amyotrophic lateral sclerosis (ALS), has recruited its first patients, the Finnish ... Read more

July 5, 2018July 5, 2018

NurOwn Now Being Produced at 2nd U.S. Manufacturing Site, Brainstorm Announces

News

BrainStorm Cell Therapeutics has partnered with the Connell and O’Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute for the manufacturing of NurOwn, a therapy candidate for amyotrophic ... Read more

June 29, 2018June 29, 2018

Brainstorm Decides Not to Offer Investigational ALS Therapy NurOwn Under Right to Try Law

News

NurOwn, an amyotrophic lateral sclerosis (ALS) treatment candidate, will not be made available under the new Right to Try Act at this time due to a lack of funding alternatives for patients, BrainStorm Cell Therapeutics announced ... Read more

March 5, 2018March 5, 2018

Genervon Continues to Focus on Nerve Cell Development Factor as ALS Treatment

News

Genervon Biopharmaceuticals says its efforts to develop treatments for ALS and other neurodegenerative diseases continue to focus on a factor that regulates stem cells’ evolution into nerve cells. It continues ... Read more

July 19, 2017

Boston and San Francisco Hospitals Will Take Part in Phase 3 Trial of NurOwn for ALS

News

Massachusetts General Hospital in Boston and California Pacific Medical Center in San Francisco will be among the sites where ALS patients will take in a Phase 3 clinical trial of BrainStorm Cell ... Read more

July 7, 2017

Worldwide Clinical Trials Picked to Manage Phase 3 Study of NurOwn for ALS

News

Worldwide Clinical Trials was selected as the Clinical Research Organization (CRO) to run a Phase 3 study of the investigational stem-cell therapy NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm Cell ... Read more

April 26, 2016April 26, 2016

Clinical Data of Promising ALS Drug Edaravone Presented at AAN Annual Meeting

News

Results from the Phase 3 trial of edaravone (MCI-186) in amyotrophic lateral sclerosis (ALS) were presented by Mitsubishi Tanabe Pharma Corporation at the 68th Annual Meeting of the American Academy of Neurology held April 15-21 in Vancouver, ... Read more

Pin It on Pinterest